Asx Occ News Today

Orthocell Limited (ASX:OCC – Get Free Report) insider John Wielen acquired 35,000 shares of the firm’s stock in a transaction dated Monday, April 15th. The stock was bought at an average price of A$0.39 ($0.25) per share, with a total value of A$13,650.00 ($8,806.45). Orthocell Stock Performance The company has a current ratio of 4.60, […]

Orthocell Limited (ASX:OCC – Get Rating) insider Paul Anderson bought 31,343 shares of the stock in a transaction that occurred on Friday, June 9th. The stock was acquired at an average price of A$0.36 ($0.24) per share, for a total transaction of A$11,252.14 ($7,602.80). Orthocell Price Performance The company has a quick ratio of 5.07, […]

Orthocell Ltds (ASX:OCC) Paul Anderson speaks to Proactive following the news its been granted patents for its CelGro® collagen rope in China and...

China and Hong Kong have granted patents to the product, which is used to augment ligament repair surgeries.

China and Hong Kong have granted patents to the product, which is used to augment ligament repair surgeries.

Orthocell is well-positioned to establish CelGro® as the best-in-class membrane for bone and soft tissue repair and to realise multiple commercial...

Orthocell identifying opportunities for expedited approval of CelGro after breakthrough results Orthocell Ltds (ASX:OCC) Paul Anderson caught up with Proactive soon after receiving positive results from a US 510(k) animal pilot study, indicating that CelGro® facilitates superior nerve regeneration when compared to the market-leading nerve repair device - restoring the sciatic nerve to a pre-injured state. As a result of this breakthrough nerve regeneration data, and in light of the previously...

Orthocell’s CelGro® study results open up new US market access strategy The breakthrough results position CelGro® as the potential market leader in nerve regeneration and restoration of voluntary muscle control in patients with tetraplegia or paralysed upper limbs with a strategic evaluation of medical device US regulatory pathways underway. Further CelGro® nerve clinical trial data from all patients at 12 months post treatment is on track for release in the current quarter. ...

US market clearance provides a pathway for OCC to continue driving the development of CelGro collagen medical device in the key peripheral nerve repair...

Orthocell Ltds (ASX:OCC) Paul Anderson caught up with Proactives Andrew Scott soon after announcing theyve received Food and Drug Administration’s...